Related references
Note: Only part of the references are listed.Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects
David C. Griffith et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens
Sirijan Santajit et al.
BIOMED RESEARCH INTERNATIONAL (2016)
Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects
Eric Wenzler et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases
Scott J. Hecker et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion
PK Dandekar et al.
PHARMACOTHERAPY (2003)
Share Paper
